CLINICAL TRIAL / CIRB24-1060

NRG GY014: A Phase II Study of Tazemetostat (EPZ 6438) (IND 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma